#1 Clinical Trials Search in Europe

Study on Trametinib Dimethyl Sulfoxide for Children with Refractory Histiocytosis Not Responding to Conventional Treatment

2 1 1 1

What is this study about?

This clinical trial is focused on studying a condition known as histiocytic cell proliferation, which involves an abnormal increase in certain immune cells. The trial is testing a medication called Trametinib Dimethyl Sulfoxide, which is taken as a film-coated tablet. The purpose of the study is to evaluate the safety, effectiveness, and how well patients tolerate this drug, as well as to determine the best duration of treatment for children whose condition has not improved with standard therapies.

Participants in the study will receive the medication Trametinib to see if it can help manage their condition, especially if they have not responded to other treatments like Vemurafenib. The study will also include a comparison with a placebo to better understand the drug’s effects. The trial will monitor participants over a period to assess their response to the treatment and any side effects they may experience.

The study aims to find the right dose of Trametinib for children under 18, ensuring it is similar to the dose recommended for adults. Throughout the trial, various health checks, including laboratory tests and heart monitoring, will be conducted to ensure the safety of the participants. The trial will also look at how long patients can live without the disease getting worse and the overall survival rate. The study is expected to continue until March 2026.

1 joining the study

Participation begins after signing an informed consent form. This document confirms understanding and agreement to participate in the study, including the use of the drug trametinib.

2 initial assessment

An initial assessment is conducted to confirm eligibility. This includes checking for the absence of mutations in the BRAF gene or previous failure of vemurafenib treatment.

The assessment may involve reviewing medical history and previous treatments, such as vinblastine and prednisolone, or other second-line treatments.

3 treatment with trametinib

The drug trametinib dimethyl sulfoxide is administered orally. The dosage and duration are optimized based on individual needs and responses.

Regular monitoring is conducted to assess the safety and effectiveness of the treatment. This includes checking vital signs, laboratory tests, and performing echocardiography and ECG.

4 monitoring and follow-up

Throughout the treatment, event-free survival (EFS) is monitored, along with any adverse events.

Progression-free survival (PFS), overall survival (OS), and overall response rate (ORR) are also evaluated.

The reactivation rate of the disease is assessed after two years.

5 completion of the study

The study is estimated to conclude by March 30, 2026. Upon completion, a final assessment is conducted to evaluate the overall outcomes and any long-term effects of the treatment.

Who Can Join the Study?

  • The patient must have a condition called histiocytic cell proliferation.
  • The patient must be a child or teenager, as the study is for juvenile patients.
  • The patient must not have changes, called mutations, in a specific part of their genes known as the BRAF gene. If they do have these changes, they must have tried a treatment called Vemurafenib and it did not work.
  • The patient must have tried other treatments and they did not work. This includes:
    • The disease got worse during the first or second treatment, which should have included a medicine called Vinblastine and another called prednisolone, or other medicines like Cytosine Arabinoside or Cladribine.
    • The disease came back after getting better with the first treatment.
    • The disease got worse during or after using Vemurafenib.
    • The patient shows signs of a brain condition seen in an MRI scan.
  • The patient or their guardian must agree to participate in the study by signing a form called informed consent.
  • If the patient is old enough to have children, they must agree to use effective contraception during the study and for at least one year after stopping the study medicine.
  • The patient must be part of another study called the HISTIOGEN trial.
  • The study is open to both male and female patients.

Who Cannot Join the Study?

  • Patients who have a different condition than histiocytic cell proliferation. This is a condition where certain immune cells grow too much.
  • Patients who are not juvenile. This means the study is only for children and young people.
  • Patients who have not tried Vemurafenib treatment before. Vemurafenib is a medication used to treat certain types of cancer.
  • Patients who are not BRAF negative. BRAF is a gene, and being BRAF negative means the gene does not have a specific mutation.
  • Patients who are not refractory to treatment. Refractory means the disease does not respond to treatment.
  • Patients who are not within the specified age range. The study is for a specific age group.
  • Patients who are not part of the specified clinical trial group. This means the study is for a specific group of patients.
  • Patients who are not considered part of a vulnerable population. This refers to groups who may need special protection in research.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

No sites found in this category

Other Sites

Site Name City Country Status
Instytut Matki I Dziecka Warsaw Poland

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Poland Poland
Not recruiting
01.04.2021

Trial locations

Investigated drugs:

Trametinib is a medication used in this trial to help treat juvenile patients with a condition called refractory histiocytosis. This condition is difficult to treat, and Trametinib is being tested to see if it can help improve the symptoms or manage the disease better. The trial aims to find the best time and amount of Trametinib to use for these patients.

Vemurafenib is another medication that some patients in the trial may have used before. It is typically used to treat certain types of cancer, but in this trial, it is relevant because the patients have not responded well to it. The trial is exploring if switching to Trametinib can be more effective for these patients.

Investigated diseases:

Histiocytic Cell Proliferation – This condition involves an abnormal increase in the number of histiocytes, which are a type of immune cell. These cells can accumulate in various tissues and organs, potentially leading to damage and dysfunction. The proliferation can cause symptoms depending on where the cells gather, such as skin rashes, bone pain, or organ enlargement. It may progress slowly or rapidly, affecting the patient’s quality of life. The condition is considered rare and can vary significantly in its presentation and severity. Understanding the underlying cause of the proliferation is crucial for managing the disease effectively.

Trial ID:
2024-515896-37-00
Protocol code:
TRAM
Trial Phase:
Therapeutic exploratory (Phase II)

Other Trials to Consider

  • Study on the Use of Fludeoxyglucose (18F) in PET/CT Scans for Young Patients with Histiocytosis

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Poland

  • Study on Vemurafenib for Children with BRAF Mutation-Resistant Histiocytosis

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Poland